酚妥拉明联合维生素、抗生素治疗重症肺炎的效果及安全性分析  

Effect and safety analysis of phentolamine combined with vitamins and antibiotics in the treatment of severe pneumonia

作　　者：曾宪辉 郭德辉 廖辉明 ZENG Xian-hui;GUO De-hui;LIAO Hui-ming(Department of Critical Care Medicine,Quannan County People's Hospital,Ganzhou 341800,China)

机构地区：[1]江西省全南县人民医院重症医学科,341800

出　　处：《中国实用医药》2022年第26期7-10,共4页China Practical Medicine

基　　金：赣州市科技计划项目(项目编号:GZ2021ZSF549)。

摘　　要：目的探究酚妥拉明联合维生素、抗生素治疗重症肺炎的效果及安全性。方法80例重症肺炎患者,按照随机数字表法分为试验组与对照组,各40例。对照组使用酚妥拉明联合抗生素治疗,试验组在对照组基础上联合使用维生素D治疗。比较两组临床疗效、不良反应发生率、症状改善时间、血清炎症指标、血气指标。结果试验组治疗总有效率为97.50%,高于对照组的82.50%,差异有统计学意义(P<0.05)。试验组不良反应发生率为5.00%,与对照组的7.50%比较,差异无统计学意义(P>0.05)。试验组咳嗽改善时间(2.78±0.64)d、肺部啰音改善时间(3.18±0.45)d、发热改善时间(1.01±0.15)d均短于对照组的(3.48±0.78)、(5.78±0.67)、(2.45±0.21)d,差异有统计学意义(P<0.05)。治疗后,两组白细胞计数(WBC)、C反应蛋白(CRP)、降钙素原(PCT)水平均较治疗前降低,且试验组WBC(8.64±0.78)×10^(9)/L、CRP(67.64±5.15)mg/L、PCT(3.45±0.61)μg/L低于对照组的(10.34±1.78)×10^(9)/L、(75.61±5.34)mg/L、(5.30±0.59)μg/L,差异有统计学意义(P<0.05)。治疗后,两组氧分压(PaO_(2))、血氧饱和度(SaO_(2))均较治疗前升高,二氧化碳分压(PaCO_(2))均较治疗前降低,且试验组PaO_(2)(86.05±4.05)mm Hg(1 mm Hg=0.133 kPa)、SaO_(2)(93.34±3.02)%高于对照组的(80.03±3.64)mm Hg、(88.34±2.67)%,PaCO_(2)(38.15±2.24)mm Hg低于对照组的(43.24±2.34)mm Hg,差异有统计学意义(P<0.05)。结论重症肺炎患者接受酚妥拉明联合维生素、抗生素治疗效果显著,可促进患者症状、血气改善,减轻炎症反应。Objective To investigate the effect and safety of phentolamine combined with vitamins and antibiotics in the treatment of severe pneumonia.Methods A total of 80 patients with severe pneumonia were divided into experimental group and control group according to the random numerical table,with 40 cases in each group.The control group was treated with phentolamine combined with antibiotics,and the experimental group was treated with vitamin D on the basis of the control group.The clinical efficacy,incidence of adverse reactions,symptom improvement time,serum inflammatory indexes and blood gas indexes were compared between the two groups.Results The total effective rate of treatment in the experimental group was 97.50%,which was higher than 82.50% in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the experimental group was 5.00%,and the difference was not statistically significant compared with 7.50% in the control group(P>0.05).In the experimental group,the improvement time of cough was(2.78±0.64)d,the improvement time of pulmonary rales was(3.18±0.45)d,and the fever improvement time was(1.01±0.15)d,which were shorter than(3.48±0.78),(5.78±0.67),and(2.45±0.21)d in the control group,and the differences were all statistically significant(P<0.05).After treatment,the levels of white blood cell count(WBC),C-reactive protein(CRP)and procalcitonin(PCT)in both groups were lower than those before treatment in this group;the WBC(8.64±0.78)×10^(9)/L,CRP(67.64±5.15)mg/L,PCT(3.45±0.61)μg/L in the experimental group were lower than(10.34±1.78)×10^(9)/L,(75.61±5.34)mg/L,(5.30±0.59)μg/L in the control group;the differences were all statistically significant(P<0.05).After treatment,the arterial partial pressure of oxygen(PaO_(2))and blood oxygen saturation(SaO_(2))in both groups were increased compared with those before treatment in this group,and the arterial partial pressure of carbon dioxide(PaCO_(2))were decreased compared with those before treatmen

关 键 词：重症肺炎 酚妥拉明 维生素 头孢哌酮钠舒巴坦钠 疗效 不良反应 

分 类 号：R563.1[医药卫生—呼吸系统]